A colorful future of quantitative pathology: Validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays

Human Pathology

Volumn 44, Issue 1, 2013, Pages 29-38

  Huang, Wei ^a   Hennrick, Kenneth ^a   Drew, Sally ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Multiplexed immunohistochemistry; Prostate cancer; Tissue microarray; Vectra

Indexed keywords

ANDROGEN RECEPTOR; UVOMORULIN;

ARTICLE; CANCER GROWTH; CHROMOGENIC MULTIPLEXED IMMUNOHISTOCHEMISTRY; HUMAN; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; RELIABILITY; TISSUE MICROARRAY; VALIDATION STUDY;

COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870688101     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.05.009     Document Type: Article

References (36)

1. S.B. Howell DNA Microarrays for analysis of gene expression Mol Urol 3 1999 295 300
2. P. Argani, C. Rosty, and R.E. Reiter Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res 61 2001 4320 4324
3. H. Goulding, S. Pinder, and P. Cannon A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples Hum Pathol 26 1995 291 294
4. M.A. Rubin, M.P. Zerkowski, and R.L. Camp Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements Am J Pathol 164 2004 831 840
5. R.L. Camp, G.G. Chung, and D.L. Rimm Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 8 2002 1323 1327
6. J.M. Giltnane, A. Molinaro, and H. Cheng Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer Arch Pathol Lab Med 132 2008 1635 1647
7. R.M. Levenson, and J.R. Mansfield Multispectral imaging in biology and medicine: slices of life Cytometry A 69 2006 748 758
8. J.R. Mansfield, C. Hoyt, and R.M. Levenson Visualization of microscopy-based spectral imaging data from multi-label tissue sections Curr Protoc Mol Biol 84 2008 14.19.1 14.19.15
9. R. Levenson Putting the more back in morphology: spectral imaging and image analysis in the service of pathology Arch Pathol Lab Med 132 2008 748 757
10. J.R. Mansfield Cellular context in epigenetics: quantitative multicolor imaging and automated per-cell analysis of miRNAs and their putative targets Methods 52 2010 271 280
11. M.A. Rubin, M. Zhou, and S.M. Dhanasekaran Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer JAMA 287 2002 1662 1670
12. Z. Jiang, G.R. Fanger, and B.A. Woda Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases Hum Pathol 34 2003 792 796
13. S. Zha, S. Ferdinandusse, and S. Denis Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer Cancer Res 63 2003 7365 7376
14. Z. Jiang, C. Li, A. Fischer, K. Dresser, and B.A. Woda Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens Am J Clin Pathol 123 2005 231 236
15. L. Cheng, M. Nagabhushan, T.P. Pretlow, S.B. Amini, and T.G. Pretlow Expression of E-cadherin in primary and metastatic prostate cancer Am J Pathol 148 1996 1375 1380
16. R. Umbas, W.B. Isaacs, and P.P. Bringuier Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer Cancer Res 54 1994 3929 3933
17. T. Otto, K. Rembrink, M. Goepel, M. Meyer-Schwickerath, and H. Rubben E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma Urol Res 21 1993 359 362
18. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
19. S. Perner, J.M. Mosquera, and F. Demichelis TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion Am J Surg Pathol 31 2007 882 888
20. K. Park, S.A. Tomlins, and K.M. Mudaliar Antibody-based detection of ERG rearrangement-positive prostate cancer Neoplasia 12 2010 590 598
21. S.M. Falzarano, M. Zhou, and P. Carver ERG gene rearrangement status in prostate cancer detected by immunohistochemistry Virchows Arch 459 2011 441 447
22. L.A. Emtage, P.J. Dunn, and A.D. Rowse Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation Br J Urol 63 1989 627 633
23. N. Nupponen, and T. Visakorpi Molecular biology of progression of prostate cancer Eur Urol 35 1999 351 354
24. C.D. Chen, D.S. Welsbie, and C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
25. I.L. Rosner, L. Ravindranath, and B. Furusato Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy Urology 70 2007 1225 1229
26. M.J. Linja, K.J. Savinainen, O.R. Saramaki, T.L. Tammela, R.L. Vessella, and T. Visakorpi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 2001 3550 3555
27. Y. Sato Role of ETS family transcription factors in vascular development and angiogenesis Cell Struct Funct 26 2001 19 24
28. N.K. Bhat, K.L. Komschlies, and S. Fujiwara Expression of ets genes in mouse thymocyte subsets and T cells J Immunol 142 1989 672 678
29. R.L. Camp, V. Neumeister, and D.L. Rimm A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers J Clin Oncol 26 2008 5630 5637
30. N. Cerveira, F.R. Ribeiro, and A. Peixoto TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions Neoplasia 8 2006 826 832
31. R. Umbas, J.A. Schalken, and T.W. Aalders Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer Cancer Res 52 1992 5104 5109
32. S. Zhang, B. Pavlovitz, J. Tull, Y. Wang, F.M. Deng, and C. Fuller Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization Diagn Mol Pathol 19 2010 151 156
33. A.M. Hoogland, G. Jenster, and W.M. van Weerden ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer Mod Pathol 25 2012 471 479
34. S. Minner, M. Enodien, and H. Sirma ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 2011 5878 5888
35. S.D. Sweat, A. Pacelli, E.J. Bergstralh, J.M. Slezak, and D.G. Bostwick Androgen receptor expression in prostatic intraepithelial neoplasia and cancer J Urol 161 1999 1229 1232
36. M.J. Donovan, I. Osman, and F.M. Khan Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease BJU Int 105 2010 462 467